Study on the economic impact of supplementary protection certificates (SPCs), pharmaceutical incentives and rewards in Europe.

closed

The study will provide an economic evaluation of the incentives and rewards for pharmaceutical innovation in Europe and its functioning within the internal market. The study will in particular analyse the effects of SPCs for pharmaceutical uses (human and veterinary) and plant protection, data protection and market exclusivity for medicinal products for human use. Evidence on the overall impact on availability and accessibility of pharmaceutical care for patients and the pressure on health systems across the European Union will be examined. The evidence and analysis provided by this study will hence support the policymaking in those areas.